Prothena Valuation
Is 0Y3M undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0Y3M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0Y3M ($14.59) is trading below our estimate of fair value ($84.85)
Significantly Below Fair Value: 0Y3M is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0Y3M?
Key metric: As 0Y3M is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0Y3M's PS Ratio? | |
|---|---|
| PS Ratio | 6.3x |
| Sales | US$133.35m |
| Market Cap | US$811.44m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.3x |
| Enterprise Value/EBITDA | -1.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0Y3M's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.1x | ||
OXB Oxford Biomedica | 4.6x | 21.0% | UK£447.8m |
GNS Genus | 1.7x | 3.5% | UK£1.1b |
BVXP Bioventix | 14.4x | n/a | UK£195.7m |
AVCT Avacta Group | 7.8x | 0.4% | UK£175.6m |
0Y3M Prothena | 6.3x | 41.1% | US$811.4m |
Price-To-Sales vs Peers: 0Y3M is good value based on its Price-To-Sales Ratio (6.3x) compared to the peer average (7.1x).
Price to Sales Ratio vs Industry
How does 0Y3M's PS Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Sales vs Industry: 0Y3M is good value based on its Price-To-Sales Ratio (6.3x) compared to the European Biotechs industry average (8x).
Price to Sales Ratio vs Fair Ratio
What is 0Y3M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.3x |
| Fair PS Ratio | 4.2x |
Price-To-Sales vs Fair Ratio: 0Y3M is expensive based on its Price-To-Sales Ratio (6.3x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$14.59 | US$60.43 +314.2% | 43.4% | US$94.00 | US$24.00 | n/a | 7 |
| Nov ’25 | US$16.62 | US$61.14 +267.9% | 41.4% | US$94.00 | US$24.00 | n/a | 7 |
| Oct ’25 | US$16.67 | US$55.88 +235.1% | 43.5% | US$94.00 | US$24.00 | n/a | 8 |
| Sep ’25 | US$22.15 | US$62.50 +182.2% | 37.7% | US$94.00 | US$24.00 | n/a | 8 |
| Aug ’25 | US$22.42 | US$64.75 +188.8% | 36.1% | US$94.00 | US$28.00 | n/a | 8 |
| Jul ’25 | US$20.53 | US$64.75 +215.4% | 36.1% | US$94.00 | US$28.00 | n/a | 8 |
| Jun ’25 | US$21.19 | US$64.75 +205.6% | 36.1% | US$94.00 | US$28.00 | n/a | 8 |
| May ’25 | US$21.99 | US$66.09 +200.5% | 32.3% | US$94.00 | US$34.00 | n/a | 10 |
| Apr ’25 | US$24.91 | US$65.72 +163.8% | 31.0% | US$94.00 | US$34.00 | n/a | 11 |
| Mar ’25 | US$28.30 | US$66.08 +133.5% | 30.0% | US$94.00 | US$35.00 | n/a | 11 |
| Feb ’25 | US$27.93 | US$73.24 +162.2% | 29.7% | US$100.00 | US$36.00 | n/a | 12 |
| Jan ’25 | US$36.58 | US$81.66 +123.2% | 30.9% | US$129.00 | US$43.00 | n/a | 12 |
| Dec ’24 | US$33.90 | US$83.45 +146.2% | 30.7% | US$129.00 | US$43.00 | n/a | 11 |
| Nov ’24 | US$35.67 | US$87.89 +146.4% | 26.2% | US$129.00 | US$52.90 | US$16.62 | 10 |
| Oct ’24 | n/a | US$93.44 0% | 21.1% | US$129.00 | US$60.00 | US$16.67 | 9 |
| Sep ’24 | US$54.76 | US$93.44 +70.7% | 21.1% | US$129.00 | US$60.00 | US$22.15 | 9 |
| Aug ’24 | US$62.80 | US$93.33 +48.6% | 21.2% | US$129.00 | US$60.00 | US$22.42 | 9 |
| Jul ’24 | US$68.14 | US$93.00 +36.5% | 20.2% | US$129.00 | US$60.00 | US$20.53 | 10 |
| Jun ’24 | US$64.69 | US$92.10 +42.4% | 18.7% | US$120.00 | US$60.00 | US$21.19 | 10 |
| May ’24 | n/a | US$85.60 0% | 20.0% | US$120.00 | US$55.00 | US$21.99 | 10 |
| Apr ’24 | n/a | US$84.10 0% | 21.6% | US$120.00 | US$55.00 | US$24.91 | 10 |
| Mar ’24 | US$55.17 | US$84.10 +52.4% | 21.6% | US$120.00 | US$55.00 | US$28.30 | 10 |
| Feb ’24 | US$54.27 | US$84.60 +55.9% | 21.0% | US$120.00 | US$56.00 | US$27.93 | 10 |
| Jan ’24 | US$59.80 | US$83.44 +39.5% | 22.3% | US$120.00 | US$55.00 | US$36.58 | 9 |
| Dec ’23 | US$61.81 | US$80.89 +30.9% | 23.5% | US$120.00 | US$55.00 | US$33.90 | 9 |
| Nov ’23 | US$64.24 | US$77.22 +20.2% | 22.0% | US$110.00 | US$52.00 | US$35.67 | 9 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€62.80
7D
1.9%
1Y
12.1%
hVIVO
UK£134.7m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.20
7D
-16.8%
1Y
2.1%
Regeneron Pharmaceuticals
US$80.6b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$750.19
7D
0.5%
1Y
-5.7%